SCHEMBL12431032

SCHEMBL12431032

CC(=O)Nc1ccc(Oc2cc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 10/20 0.58
▸ AURKB Q96GD4 9/20 0.58
▸ GSK3B P49841 6/20 0.58
▸ SRC P12931 5/20 0.58
▸ AURKC Q9UQB9 1/20 0.58
▸ GSK3A P49840 1/20 0.55
▸ HTT P42858 1/20 0.51
▸ IGF1R P08069 2/20 0.46
▸ TNIK Q9UKE5 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ MITF O75030 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ RAD52 P43351 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430982 0.81 AURKB (0.70) AURKAAURKBGSK3BSRCAURKC
SCHEMBL3961728 0.78 AURKA (0.52) AURKAAURKBGSK3BSRCAURKC
SCHEMBL13054762 0.78 GSK3B (0.52) AURKAAURKBGSK3BSRCGSK3A
SCHEMBL12431076 0.78 GSK3B (0.53) AURKAAURKBGSK3BSRCGSK3A
SCHEMBL7047559 0.76 AURKA (0.78) AURKAAURKBGSK3BSRCAURKC
SCHEMBL12431050 0.76 AURKA (0.55) AURKAAURKBGSK3BSRCAURKC
SCHEMBL12430887 0.75 AURKA (0.68) AURKAAURKBGSK3BSRCAURKC
SCHEMBL12430904 0.74 AURKA (0.53) AURKAAURKBGSK3BSRCAURKC
SCHEMBL4833121 0.73 AURKA (0.70) AURKAAURKBGSK3BSRCAURKC
SCHEMBL12430555 0.73 AURKA (1.00) AURKAAURKBGSK3BSRCAURKC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 — — US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 — — US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 — — US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKA 3/4885AURKB 7/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback